At the upcoming ECCO’24 Congress in Stockholm, the Epidemiological Committee (EpiCom) will hold its 7th Workshop on Wednesday, February 21.
In the dynamic landscape of healthcare, patients are now assuming a pivotal role beyond their traditional status as care recipients. They are emerging as active partners, capable of contributing invaluable insights to medical research. The theme of the 7th EpiCom Workshop will be "The patient as an Epidemiologist", and the workshop will aim to shed light on the empowering potential of patient involvement, underscoring the significance of utilising appropriate tools to assess clinically relevant outcomes. Moreover, it will emphasise the pivotal role of digital tools in enabling patients to directly contribute to the research process.
In the past, IBD was believed to be predominantly a disease of the Western world. However, recent studies have shown a rapidly increasing incidence of IBD in newly developing areas such as the Middle East, South America and Asia. By the middle of this century, the prevalence of IBD in low and lower-middle income countries (LLMICs) and newly industrialised nations may surpass that in the West. At the same time, the compound prevalence in the Western world and increasing health care costs will add to the challenges in IBD care. As a result of these epidemiological trends, IBD is projected to be an increasing global health burden.
As a result of my D-ECCO Travel Award, I was able to spend time at the San Filippo Neri Hospital in Rome during January 2023. There I collaborated with a team at the IBD Unit, UOC Gastroenterology. During my stay, I summarised the studies on nutritional determinants of bone mineral density among patients with Crohn’s Disease and Ulcerative Colitis which my colleagues and I had conducted in the previous year. I collected data from food frequency questionnaires and laboratory tests, including with respect to calcium, vitamin D, folic acid and homocysteine levels. Additionally, I started planning future research on the impact of MTHFR gene polymorphism on folic acid and homocysteine status and on bone mineral density in patients suffering from IBD. I also had the opportunity to learn about the standard of care for IBD patients in Italy.
Deciphering the bioactive role of extracellular matrix fragments (matrikines) in Crohn's Disease (CD) fibrostenosis as potential therapeutic targets and biomarkers
To evaluate the in vitro effect of selected novel matrix-derived peptides (matrikines) that specifically appear in the intestinal tissue of patients with Crohn’s Disease (CD) fibrostenosis on primary human intestinal myofibroblasts (iMFBs).
Aim 1: To characterise the inter-/intra-individual composition of the mycobiome of patients with IBD and healthy controls utilising a variety of sample types and methodological techniques.
Aim 2: To provide a large dataset of fungal internal transcribed spacer (ITS) rRNA sequencing data to complement the bacterial 16S rRNA analysis underway in-house.
Multiple patient, disease and pharmacokinetic (including anti-TNF drug and antibody concentrations) factors, as well as a limited number of proteomic markers, have been implicated in anti-TNF treatment failure. However, their relative effects and interactions have not been fully explored. We aimed to replicate previously postulated serological markers and to identify novel inflammatory and immune response proteomic markers related to anti-TNF treatment failure in patients with active luminal Crohn’s Disease.
This project aimed to understand the effects that crucial IBD epithelial stress factors (i.e. ATG16L1 and XBP1 impairments) might have in enteric fibroblasts and neurons.
Tim Raine is a consultant gastroenterologist at Addenbrookes Hospital in Cambridge and an honorary faculty member of the Wellcome Trust Sanger Institute. He is a mucosal immunologist, and alongside translational science work, he is also heavily involved in clinical trials and guideline development. Despite his relative youth, Tim has been in and around ECCO for many years and is well known to the ECCO Community. After chairing both Y-ECCO and GuiCom, he is now a member of SciCom, reflecting the breadth of his involvement with IBD. I had the opportunity to discuss his work with ECCO and his journey into life as a clinician-scientist.
The Y-ECCO Mentorship Forum is an educational event designed to foster networking and prepare the career of young gastroenterologists with a particular interest in Inflammatory Bowel Disease. In June 2023, the second edition of the Forum took place in beautiful Vienna, and it certainly did not disappoint.
Biomarkers for the prediction of disease onset and disease course in Ulcerative Colitis (UC) represent an ongoing and important area of unmet need. However, discovery and validation of such biomarkers has been complicated by the wide heterogeneity in disease presentation and variability in disease course [1]. Despite many initial biomarker discovery efforts in UC focusing on biopsy-based approaches, it has increasingly been recognised that non-invasive blood-based biomarkers would likely have more clinical utility, including because of their ease of collection and high rates of patient acceptance [2, 3].
Previous studies have discovered a novel autoantibody against integrin αvβ6 (anti-αvβ6) in the serum of UC patients, with strong discriminative ability for diagnosis of UC. Integrin αvβ6 plays a critical role in maintaining epithelial barrier integrity and suppressing epithelial inflammation [4–7].
Alicja Ewa Ratajczak-Pawłowska
Robin Dart
Gabriele Dragoni